Degenerative/myxomatous mitral valve disease is the most common heart disease in dogs. Progression of the disease varies amongst individuals however, if heart failure is reached, median survival time remains less than 1 year with medical intervention alone.
In humans the gold standard treatment is mitral valve repair (MVR), or replacement in select cases. MVR is an increasingly recognised treatment modality in dogs and is now recognised in the latest ACVIM guidelines.
It is important that owners and veterinarians are aware of all treatment options when making decisions on individual pet care and an understanding of this option for this common heart disease is therefore important. This webinar will outline the condition and optimal patient selection, the steps of the surgery and aftercare to gain a broad understanding of the process and results and expectations afterwards, with a particular focus on information most relevant to a primary care setting.
Language: English
more Information how online webinars work
2 hours according to § 10(2) of the ATF Statutes as mandatory continuing education for ATF members.
ATF hours are recognized by the ÖTK as educational hours.
Recognition according to the guidelines of the Society of Swiss Veterinarians is possible.
The accreditation of CE Points is approved under the condition of a positive completion of the test in the specified period and is valid from November 19, 2025 - November 19, 2026
Altavoz:
Poppy Bristow
BVetMed, MVetMed, PGCertVetEd, FHEA, DipECVS, MRCVS, ECVS and RCVS, Recognised Specialist in Small Animal Surgery (Soft Tissue)
